Taiwan · Delayed Price · Currency is TWD CH Biotech R&D Statistics
Total Valuation
CH Biotech R&D has a market cap or net worth of TWD 9.47 billion. The enterprise value is 9.57 billion.
| Market Cap | 9.47B |
| Enterprise Value | 9.57B |
Important Dates
The next estimated earnings date is Friday, August 15, 2025.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | Mar 20, 2025 |
Share Statistics
CH Biotech R&D has 102.80 million shares outstanding. The number of shares has increased by 4.39% in one year.
| Current Share Class | 102.80M |
| Shares Outstanding | 102.80M |
| Shares Change (YoY) | +4.39% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 20.51% |
| Owned by Institutions (%) | n/a |
| Float | 39.21M |
Valuation Ratios
The trailing PE ratio is 20.88.
| PE Ratio | 20.88 |
| Forward PE | n/a |
| PS Ratio | 5.69 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.54 |
| P/FCF Ratio | 30.12 |
| P/OCF Ratio | 18.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.10, with an EV/FCF ratio of 30.46.
| EV / Earnings | 20.96 |
| EV / Sales | 5.75 |
| EV / EBITDA | 13.10 |
| EV / EBIT | 17.87 |
| EV / FCF | 30.46 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.17 |
| Quick Ratio | 1.06 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 1.05 |
| Debt / FCF | 2.44 |
| Interest Coverage | 34.88 |
Financial Efficiency
Return on equity (ROE) is 17.16% and return on invested capital (ROIC) is 9.66%.
| Return on Equity (ROE) | 17.16% |
| Return on Assets (ROA) | 8.09% |
| Return on Invested Capital (ROIC) | 9.66% |
| Return on Capital Employed (ROCE) | 18.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.93 |
Taxes
In the past 12 months, CH Biotech R&D has paid 112.95 million in taxes.
| Income Tax | 112.95M |
| Effective Tax Rate | 19.85% |
Stock Price Statistics
The stock price has increased by +13.85% in the last 52 weeks. The beta is 0.08, so CH Biotech R&D's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +13.85% |
| 50-Day Moving Average | 79.95 |
| 200-Day Moving Average | 80.46 |
| Relative Strength Index (RSI) | 71.16 |
| Average Volume (20 Days) | 112,227 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CH Biotech R&D had revenue of TWD 1.66 billion and earned 456.71 million in profits. Earnings per share was 4.41.
| Revenue | 1.66B |
| Gross Profit | 1.39B |
| Operating Income | 536.43M |
| Pretax Income | 568.87M |
| Net Income | 456.71M |
| EBITDA | 705.32M |
| EBIT | 536.43M |
| Earnings Per Share (EPS) | 4.41 |
Balance Sheet
The company has 660.77 million in cash and 767.03 million in debt, giving a net cash position of -106.26 million or -1.03 per share.
| Cash & Cash Equivalents | 660.77M |
| Total Debt | 767.03M |
| Net Cash | -106.26M |
| Net Cash Per Share | -1.03 |
| Equity (Book Value) | 2.68B |
| Book Value Per Share | 26.06 |
| Working Capital | 198.28M |
Cash Flow
In the last 12 months, operating cash flow was 507.73 million and capital expenditures -193.38 million, giving a free cash flow of 314.35 million.
| Operating Cash Flow | 507.73M |
| Capital Expenditures | -193.38M |
| Free Cash Flow | 314.35M |
| FCF Per Share | 3.06 |
Margins
Gross margin is 83.61%, with operating and profit margins of 32.23% and 27.44%.
| Gross Margin | 83.61% |
| Operating Margin | 32.23% |
| Pretax Margin | 34.17% |
| Profit Margin | 27.44% |
| EBITDA Margin | 42.37% |
| EBIT Margin | 32.23% |
| FCF Margin | 18.88% |
Dividends & Yields
This stock pays an annual dividend of 4.10, which amounts to a dividend yield of 4.31%.
| Dividend Per Share | 4.10 |
| Dividend Yield | 4.31% |
| Dividend Growth (YoY) | 0.24% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 80.81% |
| Buyback Yield | -4.39% |
| Shareholder Yield | -0.16% |
| Earnings Yield | 4.82% |
| FCF Yield | 3.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2022. It was a forward split with a ratio of 1.15.
| Last Split Date | Jul 26, 2022 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
CH Biotech R&D has an Altman Z-Score of 4.71 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.71 |
| Piotroski F-Score | 6 |